| Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better | Frank Vinluan | 06/19/20 | Raleigh Durham |
| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track | Mandy Jackson | 06/12/20 | National |
| Merck’s Keytruda Fails Pivotal Bladder Cancer Study, Sinks First-Line Hopes | Frank Vinluan | 06/10/20 | New York |
| Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
| Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff | Frank Vinluan | 02/05/20 | New York |
| Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex | Frank Vinluan | 01/06/20 | New York |
| Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone | Frank Vinluan | 09/06/19 | National |
| Merck Data Are Another Step for Immunotherapy in Breast Cancer | Ben Fidler | 07/29/19 | New York |
| Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More | Frank Vinluan | 04/26/19 | National |
| Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer | Frank Vinluan | 04/22/19 | New York |
| Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More | Frank Vinluan | 02/22/19 | National |
| Bio Roundup: Dunsire’s Danish, Price Hikes, Rare-Disease Race & More | Alex Lash | 07/06/18 | National |
